Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

OBX-115

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells · developed by Obsidian Therapeutics

Phase 1/2 Most advanced trial

OBX Developer

1 Registered trials

What is OBX-115?

OBX-115 is a tumor-infiltrating lymphocyte (TIL) therapy engineered to express membrane-bound IL-15. The IL-15 enhances TIL persistence and potency, enabling the cells to target and kill tumor cells. It is studied in melanoma and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Tumor-infiltrating lymphocytes)
Mechanism: Kills target cells
Pathways: T-cell persistence, CD8+ memory T-cell maintenance
Therapy area: Oncology
Developer: Obsidian Therapeutics, Inc. (OBX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06060613	Phase 1/2	Tumor Skin	Recruiting	OBX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lung CancerMelanomaMetastatic Lung CancerMetastatic MelanomaMetastatic Non Small Cell Lung CancerNon Small Cell Lung CancerTumor Skin

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the OBX page.

Follow OBX, the company behind OBX-115

See OBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OBX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z